MiMedx Group, Inc.
MDXGHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. With a market capitalization of $640.5M, it sits in small-cap territory. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.
Market Cap
$640.5M
Beta
1.45
P/E (TTM)
21.50
P/E (Fwd)
30.00
EPS (TTM)
$0.20
EPS (Fwd)
$0.14
ROE
13.8%
ROA
8.6%
Cash
$159.8M
Total Debt
$17.6M
Free CF
$60.8M
52W Change
-33.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $159.8M in cash comfortably exceeding the $17.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $60.8M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 13.8%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $267.8M (2022) to $418.6M (2025), reflecting a 56% increase over the period.
With cash comfortably exceeding debt, MDXG has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for MiMedx Group, Inc. and its sector.